Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Annexon Inc

ANNX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$5.29

▲ +0.57%

Market Cap $1.00B · Vol 1.07M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.00B

Small Cap

Div Yield

N/A

EPS Growth

+24.28%

YoY

RSI (14)

54.62

Momentum

Beta

1.22

vs Market

52W High

$7.17

26.22% below

52W Low

$2.03

160.59% above

Volume

1.07M

Avg 1.12M

P/B

3.54

Price-to-book

ROE

-82.63%

Return on equity

Free Float

94.37%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Annexon Inc (ANNX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANNX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.22%

-4.68%

-1.49%

+8.18%

YTD

+5.38%

+122.27%

+83.68%

-72.73%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-206,690,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-82.63%
ROA · ROIC	-65.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.54
P/FCF	N/A
EPS Growth	+24.28%
Outstanding Shares	189.58M

Technical Indicators

50-Day SMA	$5.36
200-Day SMA	$5.24
RSI (14)	54.62
Beta	1.22
52-Week High	$7.17
52-Week Low	$2.03

Volume Today	1.07M
Avg Daily Volume (30D)	1.12M
Relative Volume	0.95x
Volatility (10D)	32.80
Volatility (30D)	78.39
Free Float	94.37%

Analyst Consensus

BUY

Current Price $5.29

Mean Target $15.71

52W Low$2.03 52W High$7.17

Current

Target

$2.03 $7.17

Current Analyst target

+197.06% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007QVDFH1

ISINUS03589W1027

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.